Indazole scaffold: a generalist for marketed and clinical drugs

被引：33

作者：

Cao, Yaquan ^{[1
,2
,3
,4
]}

Luo, Chunying ^{[1
,2
,3
,4
]}

Yang, Pu ^{[1
,2
,3
,4
]}

Li, Pan ^{[1
,2
,3
,4
]}

Wu, Chunli ^{[1
,2
,3
,4
]}

机构：

[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China

[2] Key Lab Adv Drug Preparat Technol, Mil Educ, Zhengzhou 450001, Peoples R China

[3] Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China

[4] Zhengzhou Key Lab New Vet Drug Preparat Innovat, Zhengzhou 450001, Peoples R China

来源：

MEDICINAL CHEMISTRY RESEARCH | 2021年 / 30卷 / 03期

关键词：

Indazole; Clinical; Drug; Disease; Pharmacology activity; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; CHEMOTHERAPY-INDUCED NAUSEA; METASTATIC BREAST-CANCER; CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL LUNG-CANCER; DUP-937; TELOXANTRONE; ANTITUMOR-ACTIVITY; MALIGNANT-MELANOMA; ANTICANCER-DRUG;

D O I：

10.1007/s00044-020-02665-7

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

More and more attention has been paid to the structurally diverse indazole analogs in recent years which are widely present in numerous commercially available drugs. Indazole-containing derivatives are endowed with a broad range of biological properties, such as anti-inflammatory, antibacterial, anti-HIV, antiarrhythmics, antifungal and antitumor activities. This review is a guide for pharmacologists who are in search of valid preclinical/clinical drug compounds where the progress, from 1966 to the present day, of approved marketed drugs containing indazole scaffold is examined.

引用

页码：501 / 518

页数：18

共 129 条

[1] PHASE-I/II TRIAL OF GRANISETRON - A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING [J].

ADDELMAN, M ;

ERLICHMAN, C ;

FINE, S ;

WARR, D ;

MURRAY, C .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) :337-341

[2]

Ali NAS, 2013, MINI-REV MED CHEM, V13, P1792

[3]

ALLEN A, 1994, EUR J CLIN PHARMACOL, V46, P159

[4] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma [J].

Andorsky, David J. ;

Kolibaba, Kathryn S. ;

Assouline, Sarit ;

Forero-Torres, Andres ;

Jones, Vicky ;

Klein, Leonard M. ;

Patel-Donnelly, Dipti ;

Smith, Mitchell ;

Ye, Wei ;

Shi, Wen ;

Yasenchak, Christopher A. ;

Sharman, Jeff P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) :215-222

[5] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications [J].

Ardini, Elena ;

Menichincheri, Maria ;

Banfi, Patrizia ;

Bosotti, Roberta ;

De Ponti, Cristina ;

Pulci, Romana ;

Ballinari, Dario ;

Ciomei, Marina ;

Texido, Gemma ;

Degrassi, Anna ;

Avanzi, Nilla ;

Amboldi, Nadia ;

Saccardo, Maria Beatrice ;

Casero, Daniele ;

Orsini, Paolo ;

Bandiera, Tiziano ;

Mologni, Luca ;

Anderson, David ;

Wei, Ge ;

Harris, Jason ;

Vernier, Jean-Michel ;

Li, Gang ;

Felder, Eduard ;

Donati, Daniele ;

Isacchi, Antonella ;

Pesenti, Enrico ;

Magnaghi, Paola ;

Galvani, Arturo .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (04) :628-639

[6] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study [J].

Awan, Farrukh T. ;

Thirman, Michael J. ;

Patel-Donnelly, Dipti ;

Assouline, Sarit ;

Rao, Arati, V ;

Ye, Wei ;

Hill, Brian ;

Sharman, Jeff P. .

LEUKEMIA & LYMPHOMA, 2019, 60 (08) :1972-1977

[7] Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia [J].

Bachegowda, Lohith ;

Morrone, Kerry ;

Winski, Shannon L. ;

Mantzaris, Ioannis ;

Bartenstein, Matthias ;

Ramachandra, Nandini ;

Giricz, Orsi ;

Sukrithan, Vineeth ;

Nwankwo, George ;

Shahnaz, Samira ;

Bhagat, Tushar D. ;

Bhattacharyya, Sanchari ;

Assal, Amer ;

Shastri, Aditi ;

Gordon-Mitchell, Shanisha ;

Pellagatti, Andrea ;

Boultwood, Jacqueline ;

Schinke, Carolina ;

Yu, Yiting ;

Guha, Chandan ;

Rizzi, James ;

Garrus, Jennifer ;

Brown, Suzy ;

Wollenberg, Lance ;

Hogeland, Grant ;

Wright, Dale ;

Munson, Mark ;

Rodriguez, Mareli ;

Gross, Stefan ;

Chantry, David ;

Zou, Yiyu ;

Platanias, Leonidas C. ;

Burgess, Laurence E. ;

Pradhan, Kith ;

Steidl, Ulrich ;

Verma, Amit .

CANCER RESEARCH, 2016, 76 (16) :4841-4849

[8] Biochemical and cell biological assays to identify and characterize DNA helicase inhibitors [J].

Banerjee, Taraswi ;

Aggarwal, Monika ;

Sommers, Joshua A. ;

Brosh, Robert M., Jr. .

METHODS, 2016, 108 :130-141

[9] Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung - A Kansas Cancer Institute and Thompson Cancer Survival Center Study [J].

Bastasch, M ;

Panella, TJ ;

Kretzschmer, SL ;

Graham, D ;

Mayo, M ;

Williamson, S .

INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) :339-342

[10] Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy [J].

Bellesoeur, Audrey ;

Carton, Edith ;

Alexandre, Jerome ;

Goldwasser, Francois ;

Huillard, Olivier .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :2801-2811

← 1 2 3 4 5 6 7 8 9 10 →